ATE489452T1 - Zirkulierende tumorzellen (ctc's): frühe beurteilung von time-to-progression, überleben und ansprechen auf therapie bei patienten mit metastasiertem krebs - Google Patents

Zirkulierende tumorzellen (ctc's): frühe beurteilung von time-to-progression, überleben und ansprechen auf therapie bei patienten mit metastasiertem krebs

Info

Publication number
ATE489452T1
ATE489452T1 AT04715133T AT04715133T ATE489452T1 AT E489452 T1 ATE489452 T1 AT E489452T1 AT 04715133 T AT04715133 T AT 04715133T AT 04715133 T AT04715133 T AT 04715133T AT E489452 T1 ATE489452 T1 AT E489452T1
Authority
AT
Austria
Prior art keywords
ctc
patients
survival
therapy
response
Prior art date
Application number
AT04715133T
Other languages
English (en)
Inventor
Jeffrey Allard
Massimo Cristofanilli
Leon Terstappen
Original Assignee
Veridex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veridex Llc filed Critical Veridex Llc
Application granted granted Critical
Publication of ATE489452T1 publication Critical patent/ATE489452T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
AT04715133T 2003-02-27 2004-02-26 Zirkulierende tumorzellen (ctc's): frühe beurteilung von time-to-progression, überleben und ansprechen auf therapie bei patienten mit metastasiertem krebs ATE489452T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45051903P 2003-02-27 2003-02-27
US52475903P 2003-11-25 2003-11-25
PCT/US2004/005848 WO2004076643A2 (en) 2003-02-27 2004-02-26 CIRCULATING TUMOR CELLS (CTC’s): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS

Publications (1)

Publication Number Publication Date
ATE489452T1 true ATE489452T1 (de) 2010-12-15

Family

ID=32930557

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04715133T ATE489452T1 (de) 2003-02-27 2004-02-26 Zirkulierende tumorzellen (ctc's): frühe beurteilung von time-to-progression, überleben und ansprechen auf therapie bei patienten mit metastasiertem krebs

Country Status (6)

Country Link
EP (1) EP1597353B1 (de)
JP (1) JP4593557B2 (de)
AT (1) ATE489452T1 (de)
CA (1) CA2516795C (de)
DE (1) DE602004030220D1 (de)
WO (1) WO2004076643A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
AU2003277153A1 (en) 2002-09-27 2004-04-19 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
PL1861509T3 (pl) * 2005-03-14 2016-01-29 Janssen Diagnostics Llc Sposób predykcji przeżywalności bez progresji i przeżywalności całkowitej przy wizytach kontrolnych w trakcie terapii u pacjentów z rozsianym rakiem piersi wykorzystujący krążące komórki nowotworowe
US20070196820A1 (en) 2005-04-05 2007-08-23 Ravi Kapur Devices and methods for enrichment and alteration of cells and other particles
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US7507534B2 (en) 2005-09-01 2009-03-24 National Health Research Institutes Rapid efficacy assessment method for lung cancer therapy
US9134237B2 (en) 2005-09-20 2015-09-15 Janssen Diagnotics, LLC High sensitivity multiparameter method for rare event analysis in a biological sample
US9127302B2 (en) 2005-09-20 2015-09-08 Janssen Diagnostics, Llc System for the detection and enumeration of suspect target cells in a mixed cell population
JP4986449B2 (ja) * 2005-12-27 2012-07-25 株式会社エスアールエル 浮遊細胞の検査方法
JP2009534666A (ja) * 2006-04-18 2009-09-24 ウェルスタット バイオロジックス コーポレイション 循環内皮細胞の検出
JP5078100B2 (ja) * 2006-04-18 2012-11-21 ウェルスタット バイオロジクス コーポレイション 循環癌細胞におけるステロイド受容体の検出および処置
US8114615B2 (en) 2006-05-17 2012-02-14 Cernostics, Inc. Method for automated tissue analysis
WO2007139895A2 (en) * 2006-05-24 2007-12-06 Cellumen, Inc. Method for modeling a disease
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
EP2029779A4 (de) 2006-06-14 2010-01-20 Living Microsystems Inc Verwendung hoch paralleler snp-genotypisierung zur fötalen diagnose
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
CN101583722A (zh) 2006-07-14 2009-11-18 阿维瓦生物科学股份有限公司 从生物学样品检测稀有细胞的方法和组合物
US20080108091A1 (en) * 2006-08-07 2008-05-08 Hennessy Bryan T Proteomic Patterns of Cancer Prognostic and Predictive Signatures
WO2008130910A1 (en) * 2007-04-19 2008-10-30 Wellstat Biologics Corporation Detection her-2/neu protein from non-isolated circulating cancer cells and treatment
EP2229441B1 (de) 2007-12-12 2014-10-01 The Board of Trustees of The Leland Stanford Junior University Verfahren und vorrichtung zur magnetischen trennung von zellen
US8008032B2 (en) 2008-02-25 2011-08-30 Cellective Dx Corporation Tagged ligands for enrichment of rare analytes from a mixed sample
US20090258365A1 (en) 2008-03-25 2009-10-15 Terstappen Leon W M M METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH
ES2620012T3 (es) 2008-09-20 2017-06-27 The Board Of Trustees Of The Leland Stanford Junior University Diagnóstico no invasivo de la aneuploidia fetal por secuenciación
CN102414562B (zh) * 2009-03-24 2019-05-07 生物概念股份有限公司 细胞捕获和分析的装置和方法
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
TWI539158B (zh) * 2010-06-08 2016-06-21 維里德克斯有限責任公司 使用血液中之循環黑色素瘤細胞預測黑色素瘤病患之臨床結果的方法。
US8790878B2 (en) 2010-07-07 2014-07-29 The Regents Of The University Of Michigan Diagnosis and treatment of breast cancer
EP3553527A1 (de) 2011-03-17 2019-10-16 Cernostics, Inc. Systeme und zusammensetzungen zur diagnose von barrett-ösophagen und verfahren zur verwendung davon
US20120252038A1 (en) * 2011-04-01 2012-10-04 Chianese David A Steroid receptor assays
JP2012022002A (ja) * 2011-09-12 2012-02-02 Veridex Llc 循環腫瘍細胞を用いる転移性乳癌患者の療法中の各追跡期間ポイントでの無増悪および全生存を予測する方法
JP6080035B2 (ja) * 2012-09-07 2017-02-15 日立化成株式会社 膜、基体及び細胞の採取方法
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
CN105264127B (zh) 2013-03-15 2019-04-09 Gpb科学有限责任公司 颗粒的片上微流体处理
US10324011B2 (en) 2013-03-15 2019-06-18 The Trustees Of Princeton University Methods and devices for high throughput purification
KR101630110B1 (ko) 2013-07-24 2016-06-13 가부시끼가이샤 옵토니쿠스 세이미쯔 말초 순환 종양 세포 또는 희소 세포 분리용 디바이스 및 말초 순환 종양 세포 또는 희소 세포 분리 방법
CN103630440A (zh) * 2013-11-28 2014-03-12 武汉大学 一种循环肿瘤细胞的富集方法
US20150160246A1 (en) 2013-12-11 2015-06-11 Analiza, Inc. Devices and methods for determining and/or isolating cells such as circulating cancer or fetal cells
US9709556B2 (en) 2013-12-11 2017-07-18 Analiza, Inc. Devices and methods for determining and/or isolating circulating cancer cells
WO2016172160A1 (en) * 2015-04-21 2016-10-27 Genentech, Inc. Compositions and methods for prostate cancer analysis
WO2016172427A1 (en) * 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
KR101701618B1 (ko) 2015-06-23 2017-02-13 국립암센터 전도성 고분자를 이용한 세포 유리 ｄｎａ 검출용 구조체 및 이의 용도
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
WO2017040686A1 (en) * 2015-09-01 2017-03-09 University Of Miami Identification of circulating cancer associated fibroblasts
EP4152001B1 (de) 2015-11-25 2025-10-22 Cernostics, Inc. Verfahren zur einstufung von barrett-ösophagus
KR101994370B1 (ko) * 2016-08-24 2019-06-28 주식회사 제놉시 항체 및 자성 나노 입자가 결합된 전도성 고분자를 포함하는 혈중 암세포 검출 및 회수용 자성 나노 구조체
CN106222161A (zh) * 2016-08-29 2016-12-14 温州医科大学附属第二医院 纳米磁颗粒捕获癌细胞的方法及其应用
BR112019018767A2 (pt) 2017-04-03 2020-05-05 Hoffmann La Roche anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, usos, método para tratar uma doença em um indivíduo e invenção
US20200408740A1 (en) * 2017-09-04 2020-12-31 Cannabics Pharmaceuticals Inc. Method for sensitivity testing of cannabinoids on patientderived tumor biopsies and ctcs
WO2021245677A1 (en) * 2020-06-05 2021-12-09 Digestix Bioscience Inc. Compositions and methods for treating dysplastic and early-stage neoplastic conditions
CN112116977B (zh) * 2020-08-12 2024-05-10 浙江大学 一种非小细胞肺癌患者疗效及预后预测系统

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993388A (en) * 1997-07-01 1999-11-30 Kattan; Michael W. Nomograms to aid in the treatment of prostatic cancer
JP2002503814A (ja) 1998-02-12 2002-02-05 イムニベスト・コーポレイション 循環ガン細胞の迅速かつ効率的な単離のための方法および試薬
US20010018192A1 (en) 1998-02-12 2001-08-30 Terstappen Leon W.M.M. Labeled cells for use as an internal functional control in rare cell detection assays
US20020172987A1 (en) * 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
US6551843B1 (en) 1999-01-29 2003-04-22 Immunivest Corporation Methods for enhancing binding interactions between members of specific binding pairs
AU2876900A (en) * 1999-02-10 2000-08-29 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids andmethods of use
US6623982B1 (en) 1999-07-12 2003-09-23 Immunivest Corporation Increased separation efficiency via controlled aggregation of magnetic nanoparticles
CA2426571A1 (en) * 2000-11-01 2002-05-10 Eleftherios P. Diamandis Detection of ovarian cancer
EP1360496A4 (de) 2001-02-16 2005-03-09 Immunivest Corp Verfahren und reagenzien zur schnellen und effizienten isolierung zirkulierender krebszellen
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
WO2003019141A2 (en) 2001-08-23 2003-03-06 Immunivest Corporation Analysis of circulating tumor cells, fragments, and debris

Also Published As

Publication number Publication date
EP1597353B1 (de) 2010-11-24
CA2516795A1 (en) 2004-09-10
EP1597353A4 (de) 2007-10-31
WO2004076643A2 (en) 2004-09-10
EP1597353A2 (de) 2005-11-23
JP2007525642A (ja) 2007-09-06
JP4593557B2 (ja) 2010-12-08
DE602004030220D1 (de) 2011-01-05
CA2516795C (en) 2013-01-15
WO2004076643A3 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
ATE489452T1 (de) Zirkulierende tumorzellen (ctc's): frühe beurteilung von time-to-progression, überleben und ansprechen auf therapie bei patienten mit metastasiertem krebs
WO2006104474A3 (en) A method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells
Caux et al. Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity
Lissoni et al. Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease
BRPI0214840B8 (pt) métodos para a detecção de mutações oncogênicas humanas, métodos automatizados para detectar uma mutação e método e ensaio para identificar um ou mais compostos tendo atividade anti-proliferativa
DE60238132D1 (de) Patientenklassifizierung
Bloomfield et al. Enhanced release of inflammatory mediators from lithium‐stimulated neutrophils in psoriasis
CN115261355B (zh) AMPKα1琥珀酰化修饰及应用
Wain et al. Mycosis fungoides with a CD56+ immunophenotype
DE60041278D1 (de) Amplifizierung von cyp24 und anwendung dafür
WO2005001138A3 (en) Breast cancer survival and recurrence
WO2003025141A3 (en) Genetic analysis for stratification of cancer risk
BRPI0503418A (pt) prognóstico para malignidade hematológica
WO2006060265A3 (en) Methods and systems for prognosis and treatment of solid tumors
WO2005024067A3 (en) Genetic analysis for stratification of breast cancer risk
Gruttadauria et al. Liver transplantation for unresectable intrahepatic cholangiocarcinoma: An Italian experience
Li et al. Bone marrow microenvironment and organ chips: Advances in tumor dormancy research
CN109295194A (zh) 银屑病易感基因lce3d和tnip1及其用途
CN114107474A (zh) Anxa6多态性位点作为基因标志物以及和甲氨蝶呤联合的银屑病试剂盒
WO2022152767A3 (en) A cxcr3+ cell or cell preparation for use in cancer treatment
RU2399057C1 (ru) Способ прогнозирования течения заболевания у больных диссеминированной меланомой кожи
Minchev et al. Does dihydropyrimidine dehydrogenase level modify plasma antioxidant capacity in colorectal cancer patients treated with fluoropyrimidines?
AL-Rubaiawi et al. The Activity of 5-Flurouracil Metabolizing Enzyme Dihydropyrimidine Dehydrogenase (DPD) and its Association with Tumor Progression and Markers (CEA, CA19. 9) in Patients with Colorectal Cancer.
Vilcek et al. A prize for the foreign-born
Masters et al. Comparative studies of the drug sensitivities of human testicular and bladder tumours in vitro

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties